Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition
Open Access
- 27 July 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7410
Abstract
Immunotherapy is now an established and efficient treatment option for many cancer patients. However, a proportion of patients still experience poor outcomes due to treatment resistance. Thus, a clear understanding of key mechanisms of resistance is needed for the development of new treatments. Here, we employ mouse models to explore an immunotherapeutic approach based on anti-MARCO (αMARCO) and anti-PD-L1 (αPD-L1) antibody-mediated targeting of tumor-associated macrophages (TAM). We demonstrate that effective immunotherapy relies on a functional endosomal pattern recognition machinery. We determine that endosomal Toll-like receptors (TLR), specifically TLR9, precondition macrophages to respond to αMARCO treatment by regulating the transcription of inflammasome components. Absence of TLRs renders TAMs unresponsive to treatment while retaining an immunosuppressive phenotype. Thus, we uncover the intracellular TLR signalling as a feature of immunotherapy efficacy, required to sensitise TAMs to treatment, and indicate that TLR targeting could be exploited to improve immunotherapeutic outcomes.Keywords
Funding Information
- Swedish Cancer Foundation
- Stiftelsen för Strategisk Forskning
This publication has 44 references indexed in Scilit:
- Macrophages: Targets for next-generation cancer immunotherapyCancer Cell, 2026
- Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33Cancer Cell, 2025
- Myeloid effector cells in cancerCancer Cell, 2024
- Toll-Like Receptor 9 Aggravates Pulmonary Fibrosis by Promoting NLRP3-Mediated Pyroptosis of Alveolar Epithelial CellsInflammation, 2024
- Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: Potential role in Sjögren’s syndromeAutoimmunity Reviews, 2021
- The role of TLR9 in stress-dependent autophagy formationBiochemical and Biophysical Research Communications, 2016
- Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic diseaseCancer Chemotherapy and Pharmacology, 2015
- Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapyCancer Immunology, Immunotherapy, 2014
- Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neckInvestigational New Drugs, 2013
- Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophagesCell, 1995